Skip to main content
S&P 5007,803.03-0.20%DOW51,234.59-0.56%NASDAQ27,498.81-0.37%BTC$83,247.00-2.73%ETH$2,560.04-5.02%GOLD$4,145.40-1.00%OIL$88.36-1.21%
Smart Investors Daily
SID Premium
CL

NASDAQ · CLNN

Clene Inc.

Healthcare · Biotechnology

$3.87

Up+$0.05 (+1.29%)

Updated Oct 7, 2026, 3:55 PM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
64.85M
P/E ratio
-2.23
Dividend yield
0.00%
52-week range
$3.25 – $8.67
Volume
44.98K
Avg. volume
192.2K

Price performance · CLNN

CLNN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

CLNN closed at $3.87 after 21 trading sessions, up 6.91% for the selected period.

Last close
$3.87
Period change
+6.91%
Period low
$3.28
Period high
$4.54
Daily close
View OHLC price history
CLNN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$3.92$4.04$3.80$3.8744.98K
Oct 5, 2026$4.09$4.11$3.80$3.91278.24K
Oct 2, 2026$4.08$4.17$3.97$4.0861.48K
Oct 1, 2026$4.10$4.1503$4.00$4.02100.03K
Sep 30, 2026$4.14$4.3269$4.01$4.0852.01K
Sep 29, 2026$4.10$4.2585$4.0601$4.1070.38K
Sep 28, 2026$4.24$4.37$4.01$4.0691.73K
Sep 25, 2026$4.15$4.4899$4.12$4.30136.46K
Sep 24, 2026$4.27$4.375$4.09$4.2147.75K
Sep 23, 2026$4.36$4.4377$4.145$4.2975.25K
Sep 22, 2026$4.51$4.6995$4.27$4.38135.77K
Sep 21, 2026$4.40$4.70$4.40$4.54109.71K
Sep 18, 2026$4.16$4.44$4.05$4.35191.43K
Sep 17, 2026$3.86$4.23$3.81$4.15138.81K
Sep 16, 2026$4.05$4.37$3.8425$3.86256.18K
Sep 15, 2026$3.25$4.18$3.25$4.02479.09K
Sep 14, 2026$3.57$3.72$3.26$3.28140.86K
Sep 11, 2026$3.72$3.76$3.52$3.57124.97K
Sep 10, 2026$3.67$3.931$3.605$3.65113.16K
Sep 9, 2026$3.67$3.84$3.48$3.72159.33K
Sep 8, 2026$3.82$3.82$3.60$3.62252.78K

Latest CLNN news

The latest Smart Investors Daily articles mentioning CLNN.

Stock researchCompany · Overview

CLNN research

Overview

Company profile and research snapshot.

Company profile

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$50.00
Implied upside
—
Analysts
—
CLNN recent ratings
DateFirmRatingTarget
May 4, 2026HC Wainwright & Co.Buy—
May 4, 2026D. Boral CapitalBuy—
Mar 13, 2026Canaccord GenuityBuy—
Mar 12, 2026D. Boral CapitalBuy—
Jan 9, 2026D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 22, 2026

Clene to Present at Upcoming Investor Conferences

SALT LAKE CITY, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will participate at the 5th Annual ROTH Healthcare Opportunities Conference and at the Lytham Partners Investor Conference Fall Event and host 1x1 investor meetings at both conferences. 5th Annual ROTH Healthcare Opportunities ConferenceDate: September 29, 2026Location: New York, NYFormat: 1x1 meetings1x1 Meetings: Please contact your ROTH representative Lytham Partners Investor Conferenc

Yahoo · Sep 21, 2026

Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA

Investment was led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders$4 million registered direct offering was priced at market under Nasdaq rulesProceeds are expected to be sufficient to fund the Company to mid-first quarter 2027, which is beyond the potential FDA decision to accept the CNM-Au8® NDA for review under the accelerated approval pathway SALT LAKE CITY, Sept. 21, 2026

Yahoo · Sep 15, 2026

Clene Announces $4 Million Registered Direct Offering

Investment led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders$4 million registered direct offering priced at market under Nasdaq rulesProceeds are expected to be sufficient to fund the Company to mid-first quarter 2027 SALT LAKE CITY, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on ALS, today announced the pricing

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By